Instruction for use: Xantinol nicotinate solution for injections 15%

Dosage form: solution for injection

Active substance: Xantinoli nicotinas

ATX

C04AD02 Xantinoli nicotinas

Pharmacological group

Antiaggregants

Nicotinates

Angioprotectors and microcirculatory correctors

Vasodilators

Correctors of cerebral circulation disorders

The nosological classification (ICD-10)

H35 Other retinal disease: retinal degeneration; Retinal degenerative changes in the eye; Subacute and chronic insufficiency of blood circulation in the retina or choroid

H81.0 Meniere's disease: Meniere's syndrome/ disease; Meniere's disease; Meniere's syndrome; Labyrinth dropsy; endolymphatic hydrops

I63 Cerebral infarction: ischemic Stroke; Ischemic brain disease; Ischemic stroke; Ischemic stroke and its consequences; Ischemic cerebral stroke; Ischemic cerebrovascular accident; Ischemic brain damage; Ischemic brain damage; ischemic conditions; Cerebral ischemia; Acute hypoxia brain; Acute cerebral ischemia; Acute ischemic cerebrovascular accident; Acute cerebral infarction; Acute ischemic stroke; Acute period of ischemic stroke; Focal cerebral ischemia; Ischemic stroke; recurrent stroke; The syndrome of Morgagni-Adams-Stokes; Chronic cerebral ischemia; cerebrovascular stroke; embolic stroke; Ischemic brain damage

I67.2 Cerebral atherosclerosis: Atherosclerosis of the arteries of the brain; Atherosclerosis of cerebral vessels; Atherosclerotic changes in cerebral vessels; Vascular diseases of the brain; Sclerotic ischemic attacks; Sclerosis of cerebral vessels

I70 Atherosclerosis: Atherosclerosis; Atherosclerosis of peripheral vessels; Atherosclerotic changes; Atherosclerotic vascular changes; Atherosclerotic disorders; spontaneous; Trombangioz obliterans; Frinlendera disease

I70.2 Atherosclerosis of arteries: arteriosclerosis obliterans; Arteriosclerosis peripheral arteries; Atherosclerosis of the arteries of the lower extremities; Atherosclerosis of peripheral arteries; Atherosclerosis limbs; Occlusive disease of the lower extremities; arteriosclerosis obliterans; Arteriosclerosis obliterans of lower limb arteries; Atherosclerosis obliterans of the upper limbs; Arteriosclerosis obliterans of lower extremities; Atherosclerosis of arteries; limb arteriopathy; Arteriosclerosis obliterans limbs; arteriosclerosis obliterans

I79.2 Peripheral angiopathy in diseases classified elsewhere: diabetic angiopathy; Angiopathy in diabetes; arteriosclerosis diabetic; Pain in lesions of peripheral nerves; Diabetic angiopathy; Diabetic microangiopathy; Diabetic vascular disease; Intermittent angioneurotic disbaziya; Macroangiopathy in diabetes; microangiopathy; Microangiopathy in diabetes mellitus; Tingling sensations in the hands and feet; Coldness in the extremities; Peripheral angiopathy; Peripheral arterial disease; Sclerosis Menkeberga; Chronic obliterating diseases of arteries

I80 Phlebitis and thrombophlebitis: Diseases of peripheral vessels; Inflammation of superficial veins; Inflammatory diseases of veins; Deep venous thrombophlebitis; The disease of veins; Disease of the veins of the lower extremities; Diseases of peripheral vessels; Migrating phlebitis; Insufficiency of veins of lower extremities; Exacerbation of chronic thrombophlebitis; Acute thrombophlebitis; Acute thrombophlebitis of superficial veins; Periphlebitis; Periflebit surface; Superficial inflammation of veins; Surface thrombophlebitis; Surface phlebitis; Thrombophlebitis; Deep vein thrombophlebitis; Thrombophlebitis superficial; Phlebitis; Phlebitis of deep veins; Phlebitis of superficial veins; Phlebopathy; Chronic thrombophlebitis; Endophlebitis

L87 Transepidermal perforations

L90.8 Other atrophic skin changes: Congenital disckeratosis; Skin Trophism; Skin aging; Increased dryness of the skin

L98.9 Skin and subcutaneous tissue disorders, unspecified: Adiponecrosisæ Atonic leatheræ Diseases of the skinæ Blisteræ Inflammatory disease of soft tissuesæ Inflammatory processes of epithelial tissuesæ Degenerative changes in the skin and mucous membranesæ Degenerative changes in the skin and mucous membranesæ Excess granulationæ Thinning of the skinæ Skin diseaseæ Maceration of the skinæ Minor skin lesionsæ Surface crack and skin abrasionæ Increased skin peelingæ Skin lesionæ Erosion of the skinæ Lipedemaæ Local non-infectious processes of skin and soft tissuesæ Disturbance of the structure of the skinæ Dysfunction of the skinæ Skin disorders

Composition and release form

15% solution for injection; In ampoules of 2 and 10 ml, in a package of 10 pcs.

1 tablet contains xanthinal nicotinate 0.15 g.

Pharmacology

Mode of action - Vasodilator.

Expands peripheral vessels, improves collateral circulation, reduces cerebral hypoxia, intensifies microcirculation in the vessels of the retina of the eye; Inhibits platelet aggregation, increases cardiac contractions.

Indications for Xantinol nicotinate solution for injections 15%

Obliterating endarteritis, Raynaud's disease, arterial thrombosis, diabetic angiopathy, retinopathy, Meniere's syndrome, arterial thrombosis, acute thrombophlebitis of the superficial and deep veins, dermatitis, trophic ulcers of the lower extremities.

Contraindications for Xantinol nicotinate solution for injections 15%

Acute bleeding, myocardial infarction, cardiac insufficiency of II and III stages, peptic ulcer of stomach and duodenum, pregnancy.

Side effects

Dizziness, heat, tingling and redness of the upper body (especially in the head and neck).

Interaction

Incompatible with alcohol and coffee.

DosageandAdministration

Intramusculary or intravenous (very slowly) - 2 ml of 15% solution 1-3 times a day. In severe cases – I.V., drip, 10 ml of 15% glucose solution for 3-4 hours.

Inside, not chewing, after eating - 1 table. (0.15 g) 3 times a day; If necessary, increase the dose to 2-3 tablets. 3 times a day. As the condition improves, the dose is reduced to 1 table. 2-3 times a day. Course - 2 months.

Precautionary measures

With caution (under the control of blood pressure) apply simultaneously with antihypertensive drugs.

Storage conditions of Xantinol nicotinate solution for injections 15%

In the dark place.

Keep out of the reach of children.

Shelf life

3 years

Do not use beyond the expiration date printed on the package.